Seven Eight Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Seven Eight Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,200	Closed	-$266K	–	744
2021 Q3	$266K	Buy	13,200 +7,300	+124%	+$202K	0.03%	510
2021 Q2	$220K	Buy	+5,900	New	+$181K	0.03%	544

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Seven Eight Capital's DRNA Position: Q4 2021 in Review

Seven Eight Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 13,200 shares — an estimated $266K sold.

Seven Eight Capital first reported a position in DRNA in Q2 2021 and held it in 2 quarters. The position peaked at $266K in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Seven Eight Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Seven Eight Capital sold 13,200 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $266K.
Seven Eight Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
Seven Eight Capital's Dicerna Pharmaceuticals, Inc. position peaked at $266K in Q3 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Seven Eight Capital's 13F filing for Q4 2021, filed 14 Feb 2022.